Abstract. Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been approved for treatment of metastatic ER+ HER2− breast cancer as monotherapy or in combination with endocrine therapy. However, ...

Abstract. Brentuximab vedotin (BV) is an antibody-drug conjugate directed against CD30 consisting of a monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent.

Solid cancers are complex “ecosystems” comprised of diverse cell types and extracellular molecules, in which heterotypic interactions significantly influence disease etiology and therapeutic response.

This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic ...

The future of cancer clinical trials requires a framework that can efficiently transform scientific discoveries to clinical utility through applications of innovative technologies and dynamic design ...

The incidence of thyroid cancer has risen dramatically in the United States over the past four decades, with similar patterns observed internationally. Thyroid cancer currently ranks as the 13th most ...

Summary:. Cell surface proteins represent ideal therapeutic targets because of their accessibility to antibodies, T cell–directed therapies, and radiotherapies, but there are only 25 therapeutically ...

These findings demonstrate that the elevation of plasma galectin-3 is a CIPN-related pathological change common to humans and mice, and that targeting galectin-3 is a therapeutic option to delay CIPN ...

Abstract. Prostate cancer is the second most frequently occurring carcinoma in males worldwide and one of the leading causes of death in men around the world. Recent studies estimate that over 1.4 ...

Abstract. SMARCA2 (BRM) and SMARCA4 (BRG1) are mutually exclusive core catalytic subunits of the SWI/SNF complexes and use their ATPase domain to regulate the composition of nucleosomes. Between 4-5% ...

Abstract. The concept of “BRCAness” was first described in 2004 to define the situation in which a homologous recombination repair (HRR) defect in a tumor relates to and phenocopies BRCA1 or BRCA2 ...

Cancer Research | 85 | 8_Supplement_1 | April 2025Journal Archive Cancer Research (1941-Present; volumes 1-current) Published twice monthly since 1987. From 1941-1986, published monthly. (ISSN ...